TKI treatment can keep CP-CML patients under favorable long-term disease control with about 90 % overall survival, 90 % complete cytogenetic response, and 90 % major molecular response which was defined as a reduction of at least 3 log in the BCR-ABL1 value from the standardized baseline level on the International Scale, at 10 years after the treatment initiation [115]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.